Progyny, Inc. (PGNY) Stock Price & Analysis
Progyny, Inc. (PGNY) closed at USD 28.4 on Thursday, October 29, 2026, up 1.90% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 27.87; the Oct 29, 2026 session ranged USD 28.03–28.58 on volume of 657,456 shares. Market capitalization is $2.18B, with a 52-week range of USD 16.1–33.07 (NMS). Source: Nexqual, retrieved October 29, 2026 at 21:02 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PGNY.md
Key facts (PGNY)
- Last four reported quarters (through Jun 30, 2026): revenue $1.31B, net income $78.6M (6.0% margin), free cash flow $178M (SEC filings).
- Valuation: P/E 27.7x (avg 43.3x at the last 3 fiscal year-ends).
- 1 of 80 tracked superinvestors hold PGNY (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 13 Form 4 filings, $1.5M; 4 not under a Rule 10b5-1 plan ($694K); 3 by opportunistic insiders (0 outside 10b5-1 plans), 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.08 on a 1–5 scale) (12 analysts), mean target USD 34.42 (range 30–40).
- Total return with dividends: 1Y +52.3% vs S&P 500 +14.4%; 5Y -53.8% vs S&P 500 +79.1%.
- Next earnings: 2026-11-04, EPS estimate USD 0.51, revenue estimate $341M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PGNY)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $501M | $787M | $1.09B | $1.17B | $1.29B | $1.31B |
| Gross profit | $112M | $167M | $239M | $253M | $304M | — |
| Operating income | $32.3M | $23.3M | $62.2M | $67.5M | $85.3M | $112M |
| Net income | $65.8M | $30.4M | $62.0M | $54.3M | $58.5M | $78.6M |
| EPS (diluted) | $0.66 | $0.30 | $0.62 | $0.57 | $0.65 | — |
| Free cash flow | $23.9M | $77.2M | $185M | $174M | $192M | $178M |
| Gross margin | 22.4% | 21.3% | 21.9% | 21.7% | 23.6% | — |
| Operating margin | 6.5% | 3.0% | 5.7% | 5.8% | 6.6% | 8.6% |
| Net margin | 13.1% | 3.9% | 5.7% | 4.7% | 4.5% | 6.0% |
| Revenue growth | +45.2% | +57.2% | +38.3% | +7.2% | +10.4% | — |
| Cash + short-term investments | $119M | $189M | $371M | $228M | $310M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PGNY)
P/E 27.7x · P/S 1.7x · P/FCF 12.2x · P/B 4.8x · FCF yield 8.19% · Earnings yield 3.61% · Buyback yield (TTM) 10.57%
P/E at fiscal year-ends: Dec 2025 39.4x, Dec 2024 30.3x, Dec 2023 60.3x.
Superinvestors (SEC 13F-HR, Q2 2026) (PGNY)
1 of 80 tracked investors hold PGNY. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.01% | $6.1M | Added +8.4% |
Insider sales (SEC Form 4, open-market, last ~7 months) (PGNY)
9 of 13 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | Cummings Melissa B | Chief Operating Officer | 1,879 | $53K | 2.7% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-23 | Swartz Allison | EVP, GC | 3,903 | $102K | 4.9% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-09-10 | Gordon Kevin K | Director | 11,500 | $321K | 62.9% | No | Too little history (no open-market trades in 2024) |
| 2026-07-14 | Cummings Melissa B | Chief Operating Officer | 2,244 | $71K | 3.1% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-04 | Livingston Mark S. | CHIEF FINANCIAL OFFICER | 2,517 | $64K | 3.3% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-06-03…2026-06-04 | Swartz Allison | EVP, GC | 1,798 | $45K | 2.1% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-02 | Livingston Mark S. | CHIEF FINANCIAL OFFICER | 279 | $7K | 0.4% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-06-02 | Clapp Geoffrey | Chief Product Officer | 1,530 | $39K | 2.5% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-01 | Scott Cheryl | Director | 7,439 | $196K | 27.3% | No | Routine (sold in Jun each year 2023–2025) |
| 2026-05-28 | Swartz Allison | EVP, GC | 2,398 | $61K | 2.7% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-27 | Gordon Kevin K | Director | 5,500 | $137K | 20.1% | No | Too little history (no open-market trades in 2024) |
| 2026-05-20 | Livingston Mark S. | CHIEF FINANCIAL OFFICER | 8,275 | $211K | 9.5% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-19 | Cummings Melissa B | Chief Operating Officer | 9,578 | $239K | 11.5% | Yes | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (PGNY)
Consensus Buy (mean 2.08 on a 1–5 scale), 12 analysts; mean target USD 34.42 (low 30, high 40).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-30 | Wells Fargo | Initiated | Overweight | $37 |
| 2026-09-08 | Citizens | Target raised | Market Outperform | $31 → $33 |
| 2026-08-21 | JP Morgan | Target raised | Neutral | $27 → $30 |
| 2026-08-20 | Wells Fargo | Initiated | Overweight | $37 |
| 2026-08-13 | Truist Securities | Target raised | Buy | $33 → $36 |
| 2026-08-12 | Barclays | Target lowered | Equal-Weight | $34 → $30 |
| 2026-07-28 | Barclays | Downgrade | Overweight → Equal-Weight | $27 → $34 |
| 2026-07-24 | BTIG | Target raised | Buy | $30 → $40 |
| 2026-07-21 | Canaccord Genuity | Target raised | Buy | $30 → $36 |
| 2026-07-13 | Keybanc | Target raised | Overweight | $30 → $35 |
Total return (dividends reinvested) (PGNY)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +52.3% | -53.8% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | +52.5% | -14.3% |
| Volatility (annualized) | 53.4% | 52.1% |
| Max drawdown | -42.6% (Jan 2026→Apr 2026) | -78.1% (Nov 2021→Nov 2024) |
PGNY earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 6, 2026 | Quarter ended Jun 30, 2026 | $0.55 | $0.52 | Beat +5.8% | -10.4% |
| May 7, 2026 | Quarter ended Mar 31, 2026 | $0.50 | $0.44 | Beat +13.6% | +26.8% |
| Feb 26, 2026 | Quarter ended Dec 31, 2025 | $0.48 | $0.40 | Beat +20.0% | -17.1% |
| Jan 12, 2026 | Quarter ended Dec 31, 2025 | $0.48 | $0.40 | Beat +20.0% | -6.5% |
| Nov 6, 2025 | Quarter ended Sep 30, 2025 | $0.45 | $0.39 | Beat +15.4% | +18.5% |
| Aug 7, 2025 | — | — | — | — | -2.7% |
| Jul 8, 2025 | — | — | — | — | +10.9% |
| May 8, 2025 | — | — | — | — | -9.5% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
PGNY recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 27, 2026 | Schedule 13G/A | BlackRock, Inc.: 14.7% of shares, passive 5%+ holder (amended) |
| Aug 7, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results; Regulation FD disclosure |
| Aug 6, 2026 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 8.9% of shares, passive 5%+ holder (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
PGNY revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Fertility benefits services revenue | $230.2M | 65.7% | +7.6% |
| Pharmacy benefits services revenue | $120.3M | 34.3% | +1.2% |
| Total revenue | $350.5M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
PGNY customer concentration
In the period ended Dec 31, 2024, a single direct customer accounted for 12% of revenue, per the company's 10-K filed Feb 27, 2026. The company does not name it.
PGNY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.51 | $0.52 | -2.7% | $340.8M | 9 |
| Next quarter (ends Dec 2026) | $0.53 | $0.52 | +1.8% | $355.2M | 9 |
| Current fiscal year (ends Dec 2026) | $2.08 | $2.06 | +1.3% | $1.37B | 9 |
| Next fiscal year (ends Dec 2027) | $2.31 | $2.25 | +2.9% | $1.51B | 9 |
PGNY options: expected move
Options price a move of about ±15.7% (±$4.38) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±12.8% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 69.9% | ±15.7% |
| Dec 18, 2026 | 50 | 58.9% | ±19.2% |
| Feb 19, 2027 | 113 | 46.9% | ±22.4% |
| May 21, 2027 | 204 | 52.4% | ±32.7% |
30-day implied volatility 57.8% vs 33.4% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 21:02 UTC)
| Price | USD 28.4 |
|---|---|
| Change | ▲ 1.90% (up) |
| Previous Close | USD 27.87 |
| Open | USD 28.03 |
| Day Range | USD 28.03 – 28.58 |
| 52-Week Range | USD 16.1 – 33.07 |
| Volume | 657,456 shares |
| Market Cap | $2.18B |
| Exchange | NMS |
Technical Analysis (PGNY)
Nexqual's technical model rates PGNY "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 29, 2026 at 21:02 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.32 (neutral) |
| vs SMA50 | Above (USD 26.81) |
| MACD | 0.44 (positive) |
Analyst Ratings (PGNY)
Wall Street analysts rate PGNY "Buy" based on 12 analysts, with a mean price target of USD 34.42 (range USD 30–40), per Nexqual as of October 29, 2026 at 21:02 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 34.42 |
| High Target | USD 40 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 10 / 2 / 0 |
Earnings (PGNY)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.51 |
| Revenue Estimate | $340.76M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.55 vs est 0.52 ▲ beat |
| 2026-03-31 | USD 0.5 vs est 0.44 ▲ beat |
| 2025-12-31 | USD 0.48 vs est 0.4 ▲ beat |
| 2025-09-30 | USD 0.45 vs est 0.39 ▲ beat |
Source: Nexqual, October 29, 2026 at 21:02 UTC.
Financials & Fundamentals (PGNY)
| Total Revenue | $1.31B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.30% |
| Gross Margin | +24.57% |
| Operating Margin | +11.41% |
| Profit Margin | +6.00% |
| ROE | +16.24% |
| Debt / Equity | 0.06 |
| Current Ratio | 2.14 |
| Total Cash | $236.92M |
| Total Debt | $26.97M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $178.38M (13.6% of revenue) |
Source: Nexqual, October 29, 2026 at 21:02 UTC.
Financial Health Score (PGNY)
Nexqual rates Progyny, Inc.'s overall financial health "Solid" across five dimensions, as of October 29, 2026 at 21:02 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 25%, operating 9% (last 4 quarters to Jun 2026, SEC) |
| Balance Sheet | Strong — $237M cash vs $27M debt, net cash position |
| Cash Flow | Solid — FCF $178M (last 4 quarters to Jun 2026, SEC), 14% margin |
| Efficiency | Solid — ROE 17%, ROA 11.0% (last 4 quarters, SEC) |
Ownership (PGNY)
| Insider Ownership | +1.98% |
|---|---|
| Institutional Ownership | +109.25% |
| Shares Outstanding | 76.73M |
| Float | 70.23M |
| Short % of Float | +8.93% |
Source: Nexqual, October 29, 2026 at 21:02 UTC.
Leadership (PGNY)
Progyny, Inc. is led by Peter Anevski, CEO & Director, per Nexqual as of October 29, 2026 at 21:02 UTC.
| CEO & Director | Peter Anevski |
|---|---|
| Executive Chairman | David J. Schlanger |
| Chief Financial Officer | Mark S. Livingston |
| Chief Operating Officer | Melissa B. Cummings |
| Chief Product Officer | Geoffrey Clapp |
Major Backers & Investors (PGNY)
Notable institutional backers of Progyny, Inc. include FMR, LLC, Ameriprise Financial, Inc., Fidelity, according to Nexqual as of October 29, 2026 at 21:02 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 9.13% |
| Ameriprise Financial, Inc. | 3.6% |
| Fidelity | 3.29% |
| Touchstone Strategic TRT-Touchstone Strategic TRT-Touchstone Small Com | 2.53% |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 2.51% |
| Citadel | 2.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 15.12% |
| Vanguard Group | 10.72% |
| State Street | 3.94% |
| Geode Capital | 2.57% |
Source: Nexqual, October 29, 2026 at 21:02 UTC.
From Progyny, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- We provide our members with access to high-touch, end-to-end concierge support, including logistical assistance, clinical guidance and emotional support through our Progyny Care Advocates, or PCAs, and our in-house clinical staff, as well as access to digital tools.
- We provide our members with high-touch, end-to-end concierge support, including logistical assistance, clinical guidance and emotional support through our PCAs and our in-house clinical staff. •Access to Selective, Premier Fertility Specialist Network.
- We have retained substantially all of our clients since we launched our fertility benefits solution, and our member satisfaction is evidenced by our most recent industry-leading Net Promoter Score, or NPS, of +81 for our fertility benefits solution and +79 for Progyny Rx, our integrated pharmacy benefits solution, as of December 31, 2025.
- In order to simplify the process for our members, we offer our proprietary Smart Cycle approach.
Legal & Regulatory Risks (Item 1A, quoted)
- We operate in a highly regulated industry and must comply with a significant number of new and evolving legal and regulatory requirements, as well as complex judicial mandates, which could have an adverse impact on our business.
- We have structured our operations to comply with all laws, regulations and other requirements applicable to us directly and to our clients and vendors, but there can be no assurance that our operations will not be challenged or impacted by regulatory authorities or enforcement initiatives.
- Changes in State and Federal Laws Related to Reproductive Rights and Fertility Benefits
- HIPAA Privacy and Security Requirements
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLOV | Clover Health Investments, Corp | USD 4.58 | ▼ 4.38% |
| ALHC | Alignment Healthcare, Inc. | USD 8.06 | ▼ 1.47% |
| OSCR | Oscar Health, Inc. | USD 30.79 | ▲ 1.02% |
| MOH | Molina Healthcare Inc | USD 198.95 | ▲ 0.43% |
| CNC | Centene Corporation | USD 68.62 | ▲ 2.34% |
| HUM | Humana Inc. | USD 417.56 | ▲ 1.38% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 21:02 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt